How I treat anemia in myelofibrosis

2.

Mehta

J

,

Wang

H

,

Iqbal

SU

,

Mesa

R

.

Epidemiology of myeloproliferative neoplasms in the United States

.

Leuk Lymphoma

.

2014

;

55

(

3

):

595

-

600

.

3.

Titmarsh

GJ

,

Duncombe

AS

,

McMullin

MF

, et al.

How common are myeloproliferative neoplasms? A systematic review and meta-analysis

.

Am J Hematol

.

2014

;

89

(

6

):

581

-

587

.

4.

Nangalia

J

,

Green

TR

.

The evolving genomic landscape of myeloproliferative neoplasms

.

Hematology Am Soc Hematol Educ Program

.

2014

;

2014

(

1

):

287

-

296

.

5.

Arber

DA

,

Orazi

A

,

Hasserjian

RP

, et al.

International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data

.

Blood

.

2022

;

140

(

11

):

1200

-

1228

.

6.

Tefferi

A

,

Cervantes

F

,

Mesa

R

, et al.

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

.

Blood

.

2013

;

122

(

8

):

1395

-

1398

.

7.

Harrison

CN

,

Vannucchi

AM

,

Kiladjian

JJ

, et al.

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

.

Leukemia

.

2016

;

30

(

8

):

1701

-

1707

.

8.

Tefferi

A

,

Lasho

TL

,

Jimma

T

, et al.

One thousand patients with primary myelofibrosis: the mayo clinic experience

.

Mayo Clin Proc

.

2012

;

87

(

1

):

25

-

33

.

9.

Passamonti

F

,

Cervantes

F

,

Vannucchi

AM

, et al.

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

.

Blood

.

2010

;

115

(

9

):

1703

-

1708

.

10.

Elena

C

,

Passamonti

F

,

Rumi

E

, et al.

Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS

.

Haematologica

.

2011

;

96

(

1

):

167

-

170

.

11.

Nicolosi

M

,

Mudireddy

M

,

Lasho

TL

, et al.

Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients

.

Leukemia

.

2018

;

32

(

5

):

1254

-

1258

.

12.

Rago

A

,

Latagliata

R

,

Montanaro

M

, et al.

Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis

.

Leuk Res

.

2015

;

39

(

3

):

314

-

317

.

13.

Passamonti

F

,

Giorgino

T

,

Mora

B

, et al.

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

.

Leukemia

.

2017

;

31

(

12

):

2726

-

2731

.

14.

Guglielmelli

P

,

Lasho

TL

,

Rotunno

G

, et al.

MIPSS70: Mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis

.

J Clin Oncol

.

2018

;

36

(

4

):

310

-

318

.

15.

Tefferi

A

,

Vaidya

R

,

Caramazza

D

,

Finke

C

,

Lasho

T

,

Pardanani

A

.

Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study

.

J Clin Oncol

.

2011

;

29

(

10

):

1356

-

1363

.

16.

Pardanani

A

,

Finke

C

,

Abdelrahman

RA

,

Lasho

TL

,

Tefferi

A

.

Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis

.

Am J Hematol

.

2013

;

88

(

4

):

312

-

316

.

17.

Barosi

G

,

Magrini

U

,

Gale

RP

.

Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis?

.

Leuk Res

.

2010

;

34

(

9

):

1119

-

1120

.

18.

Cervantes

F

,

Correa

JG

,

Hernandez-Boluda

JC

.

Alleviating anemia and thrombocytopenia in myelofibrosis patients

.

Expert Rev Hematol

.

2016

;

9

(

5

):

489

-

496

.

19.

Verstovsek

S

,

Mesa

RA

,

Gotlib

J

, et al.

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

.

J Hematol Oncol

.

2017

;

10

(

1

):

55

.

20.

Verstovsek

S

,

Mesa

RA

,

Gotlib

J

, et al.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

.

N Engl J Med

.

2012

;

366

(

9

):

799

-

807

.

21.

Gupta

V

,

Harrison

C

,

Hexner

EO

, et al.

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies

.

Haematologica

.

2016

;

101

(

12

):

e482

-

e484

.

22.

Cervantes

F

,

Ross

DM

,

Radinoff

A

, et al.

Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. [published correction appears in Leukemia. 2021;35(12):3626]

.

Leukemia

.

2021

;

35

(

12

):

3455

-

3465

.

23.

Tefferi

A

,

Mesa

RA

,

Nagorney

DM

,

Schroeder

G

,

Silverstein

MN

.

Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients

.

Blood

.

2000

;

95

(

7

):

2226

-

2233

.

24.

Hernandez-Boluda

JC

,

Martinez-Trillos

A

,

Garcia-Gutierrez

V

, et al.

Long-term results of prednisone treatment for the anemia of myelofibrosis

.

Leuk Lymphoma

.

2016

;

57

(

1

):

120

-

124

.

25.

Carreau

N

,

Tremblay

D

,

Savona

M

,

Kremyanskaya

M

,

Mascarenhas

J

.

Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes

.

Blood Rev

.

2016

;

30

(

5

):

349

-

356

.

26.

Marchetti

M

,

Barosi

G

,

Balestri

F

, et al.

Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial

.

J Clin Oncol

.

2004

;

22

(

3

):

424

-

431

.

27.

Quintas-Cardama

A

,

Kantarjian

HM

,

Manshouri

T

, et al.

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis

.

J Clin Oncol

.

2009

;

27

(

28

):

4760

-

4766

.

28.

Mesa

RA

,

Yao

X

,

Cripe

LD

, et al.

Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903

.

Blood

.

2010

;

116

(

22

):

4436

-

4438

.

29.

Tefferi

A

,

Al-Ali

HK

,

Barosi

G

, et al.

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

.

Leukemia

.

2017

;

31

(

5

):

1252

.

30.

Cervantes

F

,

Alvarez-Larran

A

,

Hernandez-Boluda

JC

, et al.

Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia

.

Br J Haematol

.

2006

;

134

(

2

):

184

-

186

.

31.

Huang

J

,

Tefferi

A

.

Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level

.

Eur J Haematol

.

2009

;

83

(

2

):

154

-

155

.

32.

Cervantes

F

,

Alvarez-Larran

A

,

Hernandez-Boluda

JC

,

Sureda

A

,

Torrebadell

M

,

Montserrat

E

.

Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature

.

Br J Haematol

.

2004

;

127

(

4

):

399

-

403

.

33.

Tsiara

SN

,

Chaidos

A

,

Bourantas

LK

,

Kapsali

HD

,

Bourantas

KL

.

Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis

.

Acta Haematol

.

2007

;

117

(

3

):

156

-

161

.

34.

Cervantes

F

,

Isola

IM

,

Alvarez-Larran

A

,

Hernandez-Boluda

JC

,

Correa

JG

,

Pereira

A

.

Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results

.

Ann Hematol

.

2015

;

94

(

11

):

1791

-

1796

.

35.

Verstovsek

S

,

Gerds

AT

,

Vannucchi

AM

, et al.

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

.

Lancet

.

2023

;

401

(

10373

):

269

-

280

.

36.

Gerds

AT

,

Harrison

CN

,

Kiladjian

J-J

, et al.

Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis

.

Blood Adv

.

2024

;

8

(

17

):

4511

-

4522

.

37.

Gerds

AT

,

Vannucchi

AM

,

Passamonti

F

, et al.

A phase 2 study of luspatercept in patients with myelofibrosis-associated anemia [abstract]

.

Blood

.

2019

;

134

(

suppl 1

):

557

.

38.

Al-Ali

HK

,

Griesshammer

M

,

le Coutre

P

, et al.

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

.

Haematologica

.

2016

;

101

(

9

):

1065

-

1073

.

39.

Gupta

V

,

Guglielmelli

P

,

Hamer-Maansson

J

,

Braunstein

EM

,

Al-Ali

HK

.

Effect of new or worsening anemia on clinical outcomes in 2233 patients with myelofibrosis treated with ruxolitinib in the expanded-access jump study [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

5174

.

40.

Maffioli

M

,

Mora

B

,

Ball

S

, et al.

A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis

.

Blood Adv

.

2022

;

6

(

6

):

1855

-

1864

.

41.

McMullin

MF

,

Harrison

CN

,

Niederwieser

D

, et al.

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis

.

Exp Hematol Oncol

.

2015

;

4

:

26

.

42.

Crisà

E

,

Cilloni

D

,

Elli

EM

, et al.

The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib

.

Br J Haematol

.

2018

;

182

(

5

):

701

-

704

.

43.

Gowin

K

,

Kosiorek

H

,

Dueck

A

, et al.

Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis

.

Leuk Res

.

2017

;

60

:

31

-

35

.

44.

Oh

ST

,

Talpaz

M

,

Gerds

AT

, et al.

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

.

Blood Adv

.

2020

;

4

(

18

):

4282

-

4291

.

45.

Oh

ST

,

Mesa

RA

,

Harrison

CN

, et al.

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis

.

Blood Adv

.

2023

;

7

(

19

):

5835

-

5842

.

46.

Mesa

RA

,

Kiladjian

JJ

,

Catalano

JV

, et al.

SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naive patients with myelofibrosis

.

J Clin Oncol

.

2017

;

35

(

34

):

3844

-

3850

.

47.

Harrison

CN

,

Vannucchi

AM

,

Platzbecker

U

, et al.

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

.

Lancet Haematol

.

2018

;

5

(

2

):

e73

-

e81

.

48.

Mesa

R

,

Verstovsek

S

,

Platzbecker

U

, et al.

Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib

.

Haematologica

.

2024

;

109

(

2

):

676

-

681

.

49.

Mesa

R

,

Harrison

C

,

Oh

ST

, et al.

Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis

.

Leukemia

.

2022

;

36

(

9

):

2261

-

2268

.

50.

Gerds

AT

,

Verstovsek

S

,

Vannucchi

AM

, et al.

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study

.

Lancet Haematol

.

2023

;

10

(

9

):

e735

-

e746

.

51.

Verstovsek

S

,

Mesa

R

,

Gupta

V

, et al.

Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials

.

Blood Adv

.

2023

;

7

(

14

):

3582

-

3591

.

52.

Mascarenhas

J

,

Hoffman

R

,

Talpaz

M

, et al.

Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial

.

JAMA Oncol

.

2018

;

4

(

5

):

652

-

659

.

53.

Gerds

AT

,

Savona

MR

,

Scott

BL

, et al.

Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis

.

Blood Adv

.

2020

;

4

(

22

):

5825

-

5835

.

54.

Bose

P

,

Mohan

S

,

Oh

S

, et al.

Phase 1/2 study of the activin receptor-like kinase 2 (ALK2) inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis

.

Hemasphere

.

2023

;

7

(

suppl 3

):

e41693dd

.

55.

Gangat

N

,

Foran

JM

,

Halpern

AB

, et al.

A phase 1b trial of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

4564

.

56.

Harrison

C

,

Chee

L

,

Ross

D

, et al.

Elritercept (KER-050) demonstrated potential to treat myelofibrosis and mitigate ruxolitinib-associated cytopenias in the phase 2 restore trial [abstract]

.

HemaSphere

.

2024

;

8

(

suppl 1

):

e104

.

57.

Rampal

RK

,

Grosicki

S

,

Chraniuk

D

, et al.

Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naïve patients with myelofibrosis: results of the MANIFEST-2 randomized, double-blind, phase 3 study [abstract]

.

Blood

.

2023

;

142

(

suppl 1

). 628.

58.

Platzbecker

U

,

Santini

V

,

Fenaux

P

, et al.

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

.

Lancet

.

2024

;

403

(

10423

):

249

-

260

.